Insider trade

Director received an award of 318 ABT derivative securities

Traded Sep 30, 2026 · Filed Oct 3, 2026

Abbott LaboratoriesABT

318
Derivative units · @ $98.83

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 30, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 3, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references dividend reinvestment

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001104659-26-113285
Filed / recorded

Oct 3, 2026, 12:10 AM UTC

Added to OQRO

Oct 3, 2026, 11:40 AM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

ABBOTT LABORATORIES

Issuer CIK

1800

Ticker

ABT

Reporting person

Nita Ahuja

Relationship

Director

Security

Stock Equivalent Units

Table

Derivative (Table II)

Transaction date

Sep 30, 2026

Transaction code

A

Shares / units

318

Price per share

$98.83

Acquired / disposed

Acquired (A)

Shares owned after

771

Ownership form

Direct

Amendment

No

Footnotes from the filing

Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.